Biochemical assessment of metabolic associated fatty liver disease-Reference-Cited by-同舟云学术

Biochemical assessment of metabolic associated fatty liver disease

Published:2021-03-15 Issue:2 Volume:2 Page:199-208
ISSN:2628-491X
Container-title:Advances in Laboratory Medicine / Avances en Medicina de Laboratorio
language:en
Short-container-title:

Author:

Guerra-Ruiz Armando R.¹²^ORCID,Casals Gregori¹³,Iruzubieta Paula⁴⁵,Lalana Marta¹⁶,Leis Alba¹⁷,López Rosa María¹⁸,Crespo Javier⁴⁵,Morales-Ruiz Manuel¹⁹

Affiliation:

1. Commission on Biochemistry of Liver Disease, Spanish Society of Laboratory Medicine (SEQC-ML) , Barcelona , Spain

2. Service of Clinical Analysis, Hospital Universitario Marqués de Valdecilla , Santander , Spain

3. Service of Biochemistry and Molecular Genetics, CDB, Hospital Clinic de Barcelona, IDIBAPS, CIBEREHD , Barcelona , Spain

4. Spanish Society of Digestive Pathology (SEPD) , Madrid , Spain

5. Service of Digestive System, Hospital Universitario Marqués de Valdecilla, Clinical and Traslational Research Group on Digestive Disorders, IDIVAL , Santander , Spain

6. Service of Clinical Analysis, Hospital de Barbastro , Huesca , Spain

7. Service of Clinical Analysis and Biochemistry, Laboratori Clínic Metropolitana Nord, Hospital Universitari Germans Trias i Pujol , Badalona , Spain

8. Departments of Biochemistry and Microbiology , Unit of Liver Disease, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona , Barcelona , Spain

9. Department of Biomedicine of the Faculty of Medicine and Health Sciences , Service of Biochemistry and Molecular Genetics, Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, University of Barcelona , Barcelona , Spain

Abstract

Abstract Metabolic-associated fatty liver disease (MAFLD) is defined as fat accumulation in the liver in the presence of metabolic alterations. This disorder is generally asymptomatic and may progress to severe liver disease, which are linked to inflammation and/or fibrosis. MAFLD has a high prevalence (26%) and therefore a considerable number of patients are at high risk of having advanced liver disease. This document provides an overview of the most relevant serological markers in the characterization and diagnosis of MAFLD. An example is provided of a routine diagnostic algorithm that incorporates serological testing. A range of useful serological scores are currently available for the management of MAFLD patients, especially for the stratification of patients at risk of fibrosis. A large proportion of the population is at risk of developing severe liver disease. The integration of non-invasive serological markers in the stratification of patients at risk for liver fibrosis may contribute to improve the control and management of MAFLD patients.

Publisher

Walter de Gruyter GmbH

Link

https://www.degruyter.com/document/doi/10.1515/almed-2021-0009/pdf

Reference78 articles.

1. Eslam, M, Sanyal, AJ, George, J, Sanyal, A, Neuschwander-Tetri, B, Tiribelli, C, et al.. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 2020;158:1999–2014.e1. https://doi.org/10.1053/j.gastro.2019.11.312.

2. Eslam, M, Newsome, PN, Sarin, SK, Anstee, QM, Targher, G, Romero-Gomez, M, et al.. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol 2020;73:202–9. https://doi.org/10.1016/j.jhep.2020.03.039.

3. Younossi, Z, Anstee, QM, Marietti, M, Hardy, T, Henry, L, Eslam, M, et al.. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2018;15:11–20. https://doi.org/10.1038/nrgastro.2017.109.

4. Younossi, ZM, Koenig, AB, Abdelatif, D, Fazel, Y, Henry, L, Wymer, M. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73–84. https://doi.org/10.1002/hep.28431.

5. Chalasani, N, Younossi, Z, Lavine, JE, Charlton, M, Cusi, K, Rinella, M, et al.. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018;67:328–57. https://doi.org/10.1002/hep.29367.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chronic liver disease and management with silymarin: an introductory review of a clinical case collection;Drugs in Context;2024-01-31

2. Amorphous solid dispersion augments the bioavailability of phloretin and its therapeutic efficacy via targeting mTOR/SREBP-1c axis in NAFLD mice;Biomaterials Advances;2023-11

3. Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: The Next Threat after Viral Hepatitis;Diagnostics;2023-08-09

4. NOD-like receptors in the pathogenesis of metabolic (dysfunction)-associated fatty liver disease: Therapeutic agents targeting NOD-like receptors;Diabetes & Metabolic Syndrome: Clinical Research & Reviews;2023-07

5. Management of non-alcoholic fatty liver disease incidentally detected during other medical assessments;Drugs in Context;2023-05-11